Stephen M.  Deitsch net worth and biography

Stephen Deitsch Biography and Net Worth

CFO & Principal Fin. Officer of Paragon 28
Steve Deitsch has served as Paragon 28’s Chief Financial Officer since October 2020. He previously served as Senior Vice President and Chief Financial Officer of BioScrip, Inc. (Nasdaq: “BIOS”), which is now part of Option Care Health, Inc. (Nasdaq: “BIOS”), from April 2017 to August 2019. From August 2015 to April 2017, Mr. Deitsch served as Executive Vice President, Chief Financial Officer and Corporate Secretary of Coalfire, Inc., a leading cyber-security firm owned by The Carlyle Group. Mr. Deitsch served as the Chief Financial Officer of the Zimmer Biomet Spine, Bone Healing, and Microfixation business from July 2014 to July 2015 and as Vice President Finance, Biomet Corporate Controller from February 2014 to July 2014. Mr. Deitsch was the Chief Financial Officer of Lanx from September 2009 until it was acquired by Biomet in October 2013. From 2002 to 2009, Mr. Deitsch also served in various senior financial leadership roles at Zimmer Holdings, Inc. (now part of Zimmer Biomet, Inc.), including Vice President Finance, Reconstructive and Operations, and Vice President Finance, Europe. Mr. Deitsch has served on the board of directors of Auddia Inc., a publicly traded company, since 2019, and Green Sun Medical, a privately held medical device company, since 2017. Mr. Deitsch holds a B.S. in Accounting from Ball State University.

How do I contact Stephen M. Deitsch?

The corporate mailing address for Mr. Deitsch and other Paragon 28 executives is , , . Paragon 28 can also be reached via phone at 720-912-1332 and via email at [email protected]. Learn More on Stephen M. Deitsch's contact information.

Has Stephen M. Deitsch been buying or selling shares of Paragon 28?

Stephen M. Deitsch has not been actively trading shares of Paragon 28 over the course of the past ninety days. Learn More on Stephen M. Deitsch's trading history.

Who are Paragon 28's active insiders?

Paragon 28's insider roster includes Albert DaCosta (Co-Founder), and Stephen Deitsch (CFO & Principal Fin. Officer ). Learn More on Paragon 28's active insiders.

Are insiders buying or selling shares of Paragon 28?

In the last twelve months, Paragon 28 insiders bought shares 2 times. They purchased a total of 58,500 shares worth more than $514,915.00. In the last twelve months, insiders at the sold shares 2 times. They sold a total of 13,700 shares worth more than $254,270.00. The most recent insider tranaction occured on March, 15th when insider Albert Dacosta bought 28,000 shares worth more than $255,360.00. Insiders at Paragon 28 own 15.3% of the company. Learn More about insider trades at Paragon 28.

Information on this page was last updated on 3/15/2024.

Stephen M. Deitsch Insider Trading History at Paragon 28

See Full Table

Stephen M. Deitsch Buying and Selling Activity at Paragon 28

This chart shows Mr. Stephen M. Deitsch's buying and selling at Paragon 28 by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Paragon 28 Company Overview

Paragon 28 logo
Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.
Read More

Today's Range

Now: $8.80
Low: $8.73
High: $9.18

50 Day Range

MA: $10.92
Low: $8.87
High: $13.94

2 Week Range

Now: $8.80
Low: $7.95
High: $19.72

Volume

554,071 shs

Average Volume

527,648 shs

Market Capitalization

$729.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01